+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Company Analysis: Bayer

  • ID: 5357338
  • Company Profile
  • January 2021
  • 55 pages
  • Datamonitor Healthcare
  • Bayer AG
The publisher explores Bayer’s prescription pharmaceutical performance and outlook over 2019-29.

Snapshot
  • Overview - Bayer’s prescription drug sales will experience modest growth over the forecast period.
  • Key themes - [1] Xarelto and Eylea, Bayer’s two flagship drugs, will see robust global growth in the short term [2] Growth in China is key for several of Bayer’s franchises [3] Genitourinary remains a key therapy area, as Yaz and Mirena will drive sales growth.
Model updates (4 November 2020)
  • Eylea forecast adjusted higher due to less COVID-19 impact and revision of generic launch timing
  • Xarelto forecast adjusted higher due to strong performance globally.
Model updates (5 August 2020)
  • Adalat forecast adjusted lower due to COVID-19 impact
  • Gadavist forecast adjusted lower due to COVID-19 impact
  • Glucobay forecast adjusted lower due to volume-based procurement policy in China
  • Kogenate forecast adjusted higher due to sales
  • Mirena forecast adjusted lower due to COVID-19 impact
  • Vericiguat forecast pulled forward due to registration in Europe and Japan.
Model updates (26 April 2020)
  • Xarelto forecast adjusted higher due to higher volumes globally and stable performance in the US
  • Glucobay forecast adjusted lower due to COVID-19 impact in China
  • Jivi forecast removed due to Bayer consolidating Jivi sales with Kogenate.
Model updates (26 February 2020)
  • Eylea forecast adjusted higher due to continued strength in Europe, Japan, and the Middle East
  • Betaferon/Betaseron forecast adjusted lower due to continued market share losses in the US.
Note: Product cover images may vary from those shown
Company Background
  • Company Overview
  • Key Metrics
  • SWOT Analysis
  • Key Drug & Company Information
  • Company Comparison
Recent Earnings Review
  • Earnings Overview
  • Pharma Insights Analysis
Company Forecast
  • Prescription Pharmaceuticals Sales Outlook
  • Branded Drug Outlook
  • Launch Profile Outlook
  • Therapy Area Outlook
  • Regional Sales Outlook
  • Lifecycle Analysis
Company Profile
  • Marketed & Pipeline Drugs
  • Recent Events & Analyst Opinions
  • Upcoming Catalysts
  • Recent Insights
Clinical Trial Overview
  • Clinical Trial Snapshot
  • Clinical Trials by Country
  • Clinical Trials by Status and Phase
  • Clinical Trials by Drug
Note: Product cover images may vary from those shown
Adroll
adroll